Bone diseases: Romosozumab - on track or derailed?
- PMID: 29027994
- PMCID: PMC7176335
- DOI: 10.1038/nrendo.2017.136
Bone diseases: Romosozumab - on track or derailed?
Abstract
Romosozumab, a recently developed sclerostin inhibitor, stimulates bone formation and inhibits bone resorption, thereby markedly increasing bone mass and reducing fracture risk. But will a red flag regarding possible adverse cardiovascular events derail this promising new drug for osteoporosis?
Conflict of interest statement
Competing interests statement
The author declares no competing interests.
Comment on
-
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11. N Engl J Med. 2017. PMID: 28892457 Clinical Trial.
References
-
- Li X et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res 24, 578–588 (2009). - PubMed
-
- McClung MR et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med 370, 412–420 (2014). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
